Pain in cancer survivors

Clinical Pain Management: Cancer Pain, Second Edition

Volumn , Issue , 2008, Pages 399-410

  Paul Farquhar Smith, W ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877973584     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (120)

1. Peto R, Boreham J, Clarke M et al. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet. 2000; 355: 1822
2. Carpenter JS, Andrykowski MA, Sloan P et al. Postmastectomy/postlumpectomy pain in breast cancer survivors. Journal of Clinical Epidemiology. 1998; 51: 1285-92
3. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. Journal of Neurology. 2002; 249: 9-17
4. Cata JP, Weng HR, Lee BN et al. Clinical and experimental findings in humans and animals with chemotherapyinduced peripheral neuropathy. Minerva Anestesiologica. 2006; 72: 151-69
5. Chaudhry V, Rowinsky EK, Sartorius SE et al. Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Annals of Neurology. 1994; 35: 304-11
6. Stephens RJ, Hopwood P, Girling DJ, Machin D. Randomized trials with quality of life endpoints: are doctors’ ratings of patients’ physical symptoms interchangeable with patients’ self-ratings? Quality of Life Research. 1997; 6: 225-36
7. Hausheer FH, Schilsky RL, Bain S et al. Diagnosis, management, and evaluation of chemotherapy-induced peripheral neuropathy. Seminars in Oncology. 2006; 33: 15-49
8. Openshaw H, Beamon K, Synold TW et al. Neurophysiological study of peripheral neuropathy after high-dose Paclitaxel: lack of neuroprotective effect of amifostine. Clinical Cancer Research. 2004; 10: 461-7
9. Siau C, Xiao W, Bennett GJ. Paclitaxeland vincristineevoked painful peripheral neuropathies: Loss of epidermal innervation and activation of Langerhans cells. Experimental Neurology. 2006; 201: 507-14
10. Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: evidence for mitochondrial dysfunction. Pain. 2006; 122: 245-57
11. Lipton RB, Apfel SC, Dutcher JP et al. Taxol produces a predominantly sensory neuropathy. Neurology. 1989; 39: 368-73
12. Screnci D, McKeage MJ, Galettis P et al. Relationships between hydrophobicity, reactivity, accumulation and peripheral nerve toxicity of a series of platinum drugs. British Journal of Cancer. 2000; 82: 966-72
13. Sahenk Z, Barohn R, New P, Mendell JR. Taxol neuropathy. Electrodiagnostic and sural nerve biopsy findings. Archives of Neurology. 1994; 51: 726-9
14. Ocean AJ, Vahdat LT. Chemotherapy-induced peripheral neuropathy: pathogenesis and emerging therapies. Supportive Care in Cancer. 2004; 12: 619-25
15. Grunberg SM, Sonka S, Stevenson LL, Muggia FM. Progressive paresthesias after cessation of therapy with very high-dose cisplatin. Cancer Chemotherapy and Pharmacology. 1989; 25: 62-4
16. Dougherty PM, Cata JP, Cordella JV et al. Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain. 2004; 109: 132-42
17. Forsyth PA, Balmaceda C, Peterson K et al. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. Journal of Neuro-oncology. 1997; 35: 47-53
18. Berger T, Malayeri R, Doppelbauer A et al. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatinchemotherapy. European Journal of Cancer. 1997; 33: 1393-9
19. du BA, Schlaich M, Luck HJ et al. Evaluation of neurotoxicity induced by paclitaxel second-line chemotherapy. Supportive Care in Cancer. 1999; 7: 354-61
20. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Expert Opinion on Drug Safety. 2004; 3: 535-46
21. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981; 47: 207-14
22. Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology. 1982; 5: 649-55
23. Postma TJ, Heimans JJ. Grading of chemotherapy-induced peripheral neuropathy. Annals of Oncology. 2000; 11: 509-13
24. Postma TJ, Heimans JJ, Muller MJ et al. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Annals of Oncology. 1998; 9: 739-44
25. Postma TJ, Aaronson NK, Heimans JJ et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. European Journal of Cancer. 2005; 41: 1135-9
26. Cruccu G, Anand P, Attal N et al. EFNS guidelines on neuropathic pain assessment. European Journal of Neurology. 2004; 11: 153-62
27. Mollman JE. Cisplatin neurotoxicity. New England Journal of Medicine. 1990; 322: 126-7
28. Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Frequent off-therapy deterioration, demyelinating syndromes, and muscle cramps. Cancer. 1990; 66: 1117-23
29. Rosell R, Gatzemeier U, Betticher DC et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-smallcell lung cancer: a cooperative multinational trial. Annals of Oncology. 2002; 13: 1539-49
30. Extra JM, Marty M, Brienza S, Misset JL. Pharmacokinetics and safety profile of oxaliplatin. Seminars in Oncology. 1998; 25: 13-22
31. Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. Annals of Pharmacotherapy. 2005; 39: 128-35
32. Williams C, Collingwood M, Simera I, Grafton C. Short versus long duration infusions of paclitaxel for any adenocarcinoma. Cochrane Database of Systematic Reviews. 2003; CD003911
33. Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxelcarboplatin as first-line chemotherapy for ovarian carcinoma. Journal of the National Cancer Institute. 2004; 96: 1682-91
34. Stubblefield MD, Slovin S, Gregor-Cortelli B et al. An electrodiagnostic evaluation of the effect of pre-existing peripheral nervous system disorders in patients treated with the novel proteasome inhibitor bortezomib. Clinical Oncology (Royal College of Radiologists). 2006; 18: 410-18
35. Richardson PG, Sonneveld P, Schuster MW et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine. 2005; 352: 2487-98
36. Richardson PG, Briemberg H, Jagannath S et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. Journal of Clinical Oncology. 2006; 24: 3113-20
37. Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. New England Journal of Medicine. 2003; 348: 2609-17
38. Tseng S, Pak G, Washenik K et al. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. Journal of the American Academy of Dermatology. 1996; 35: 969-79
39. Tosi P, Zamagni E, Cellini C et al. Neurological toxicity of long-term (41yr) thalidomide therapy in patients with multiple myeloma. European Journal of Haematology. 2005; 74: 212-16
40. Bastuji-Garin S, Ochonisky S, Bouche P et al. Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients. Journal of Investigative Dermatology. 2002; 119: 1020-6
41. Eriksson T, Bjorkman S, Hoglund P. Clinical pharmacology of thalidomide. European Journal of Clinical Pharmacology. 2001; 57: 365-76
42. Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. Journal of Clinical Oncology. 2002; 20: 2895-903
43. Vahdat L, Papadopoulos K, Lange D et al. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clinical Cancer Research. 2001; 7: 1192-7
44. Savarese DM, Savy G, Vahdat L et al. Prevention of chemotherapy and radiation toxicity with glutamine. Cancer Treatment Reviews. 2003; 29: 501-13
45. Pisano C, Pratesi G, Laccabue D et al. Paclitaxel and cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clinical Cancer Research. 2003; 9: 5756-67
46. Finnerup NB, Otto M, McQuay HJ et al. Algorithm for neuropathic pain treatment: an evidence based proposal. Pain. 2005; 118: 289-305
47. Attal N, Cruccu G, Haanpaa M et al. EFNS guidelines on pharmacological treatment of neuropathic pain. European Journal of Neurology. 2006; 13: 1153-69
48. Wong GY, Michalak JC, Sloan JA, Lorprinzi CL. A phase III, double blinded, placebo controlled randomised trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy. A North Central Cancer Group Study. Journal of Clinical Oncology. 2005; 23 (Suppl. 729), Abstract 8001
49. Mitchell P, Goldstein D, Michael M et al. Addition of gabapentin to a modified FOLFOX regimen does not reduce neurotoxicity in patients with advanced colorectal cancer. Journal of Clinical Oncology. 2006; 23 (Suppl. 266), Abstract 3581
50. Macrae WA. Chronic pain after surgery. British Journal of Anaesthesia. 2001; 87: 88-98
51. Wallace MS, Wallace AM, Lee J, Dobke MK. Pain after breast surgery: a survey of 282 women. Pain. 1996; 66: 195-205
52. Stevens PE, Dibble SL, Miaskowski C. Prevalence, characteristics, and impact of postmastectomy pain syndrome: an investigation of women’s experiences. Pain. 1995; 61: 61-8
53. Tasmuth T, von SK, Hietanen P et al. Pain and other symptoms after different treatment modalities of breast cancer. Annals of Oncology. 1995; 6: 453-9
54. Fassoulaki A, Sarantopoulos C, Melemeni A, Hogan Q. Regional block and mexiletine: the effect on pain after cancer breast surgery. Regional Anesthesia and Pain Medicine. 2001; 26: 223-8
55. Vecht CJ, Van de Brand HJ, Wajer OJ. Post-axillary dissection pain in breast cancer due to a lesion of the intercostobrachial nerve. Pain. 1989; 38: 171-6
56. Foley KM. Pain syndromes in patients with cancer. Medical Clinics of North America. 1987; 71: 169-84
57. Smith WC, Bourne D, Squair J et al. A retrospective cohort study of post mastectomy pain syndrome. Pain. 1999; 83: 91-5
58. Kehlet H, Jensen TS, Woolf CJ. Persistent postsurgical pain: risk factors and prevention. Lancet. 2006; 367: 1618-25
59. Coderre TJ, Katz J, Vaccarino AL, Melzack R. Contribution of central neuroplasticity to pathological pain: review of clinical and experimental evidence. Pain. 1993; 52: 259-85
60. Carpenter JS, Sloan P, Andrykowski MA et al. Risk factors for pain after mastectomy/lumpectomy. Cancer Practice. 1999; 7: 66-70
61. Jung BF, Ahrendt GM, Oaklander AL, Dworkin RH. Neuropathic pain following breast cancer surgery: proposed classification and research update. Pain. 2003; 104: 1-13
62. Macdonald L, Bruce J, Scott NW et al. Long-term followup of breast cancer survivors with post-mastectomy pain syndrome. British Journal of Cancer. 2005; 92: 225-30
63. Katz J, Poleshuck EL, Andrus CH et al. Risk factors for acute pain and its persistence following breast cancer surgery. Pain. 2005; 119: 16-25
64. Poleshuck EL, Katz J, Andrus CH et al. Risk factors for chronic pain following breast cancer surgery: a prospective study. Journal of Pain. 2006; 7: 626-34
65. Caffo O, Amichetti M, Ferro A et al. Pain and quality of life after surgery for breast cancer. Breast Cancer Research and Treatment. 2003; 80: 39-48
66. Gulluoglu BM, Cingi A, Cakir T et al. Factors related to post-treatment chronic pain in breast cancer survivors: the interference of pain with life functions. International Journal of Fertility and Women’s Medicine. 2006; 51: 75-82
67. Tasmuth T, von SK, Kalso E. Pain and other symptoms during the first year after radical and conservative surgery for breast cancer. British Journal of Cancer. 1996; 74: 2024-31
68. Tasmuth T, Kataja M, Blomqvist C et al. Treatment-related factors predisposing to chronic pain in patients with breast cancer a multivariate approach. Acta Oncologica. 1997; 36: 625-30
69. Ishiyama H, Niino K, Hosoya T, Hayakawa K. Results of a questionnaire survey for symptom of late complications caused by radiotherapy in breast conserving therapy. Breast Cancer. 2006; 13: 197-201
70. Wood KM. Intercostobrachial nerve entrapment syndrome. Southern Medical Journal. 1978; 71: 662-3
71. Torresan RZ, Cabello C, Conde DM, Brenelli HB. Impact of the preservation of the intercostobrachial nerve in axillary lymphadenectomy due to breast cancer. Breast Journal. 2003; 9: 389-92
72. Abdullah TI, Iddon J, Barr L et al. Prospective randomized controlled trial of preservation of the intercostobrachial nerve during axillary node clearance for breast cancer. British Journal of Surgery. 1998; 85: 1443-5
73. Taylor KO. Morbidity associated with axillary surgery for breast cancer. ANZ Journal of Surgery. 2004; 74: 314-17
74. Freeman SR, Washington SJ, Pritchard T et al. Long term results of a randomised prospective study of preservation of the intercostobrachial nerve. European Journal of Surgical Oncology. 2003; 29: 213-15
75. Legeby M, Segerdahl M, Sandelin K et al. Immediate reconstruction in breast cancer surgery requires intensive post-operative pain treatment but the effects of axillary dissection may be more predictive of chronic pain. Breast. 2002; 11: 156-62
76. Barranger E, Dubernard G, Fleurence J et al. Subjective morbidity and quality of life after sentinel node biopsy and axillary lymph node dissection for breast cancer. Journal of Surgical Oncology. 2005; 92: 17-22
77. Tasmuth T, Blomqvist C, Kalso E. Chronic post-treatment symptoms in patients with breast cancer operated in different surgical units. European Journal of Surgical Oncology. 1999; 25: 38-43
78. Tasmuth T, Estlanderb AM, Kalso E. Effect of present pain and mood on the memory of past postoperative pain in women treated surgically for breast cancer. Pain. 1996; 68: 343-7
79. Amichetti M, Caffo O. Pain after quadrantectomy and radiotherapy for early-stage breast cancer: incidence, characteristics and influence on quality of life. Results from a retrospective study. Oncology. 2003; 65: 23-8
80. Gottrup H, Andersen J, Rendt-Nielsen L, Jensen TS. Psychophysical examination in patients with postmastectomy pain. Pain. 2000; 87: 275-84
81. Kairaluoma PM, Bachmann MS, Korpinen AK et al. Singleinjection paravertebral block before general anesthesia enhances analgesia after breast cancer surgery with andwithout associated lymph node biopsy. Anesthesia and Analgesia. 2004; 99 1837-43, table
82. Kairaluoma PM, Bachmann MS, Rosenberg PH, Pere PJ. Preincisional paravertebral block reduces the prevalence of chronic pain after breast surgery. Anesthesia and Analgesia. 2006; 103: 703-08
83. Misra A, Chester D, Park A. A comparison of postoperative pain between DIEP and extended latissimus dorsi flaps in breast reconstruction. Plastic and Reconstructive Surgery. 2006; 117: 1108-12
84. Rothemund Y, Grusser SM, Liebeskind U et al. Phantom phenomena in mastectomized patients and their relation to chronic and acute pre-mastectomy pain. Pain. 2004; 107: 140-6
85. Nikolajsen L, Jensen TS. Phantom limb pain. British Journal of Anaesthesia. 2001; 87: 107-16
86. Kroner K, Krebs B, Skov J, Jorgensen HS. Immediate and long-term phantom breast syndrome after mastectomy: incidence, clinical characteristics and relationship to premastectomy breast pain. Pain. 1989; 36: 327-34
87. Kroner K, Knudsen UB, Lundby L, Hvid H. Long-term phantom breast syndrome after mastectomy. Clinical Journal of Pain. 1992; 8: 346-50
88. Flor H, Elbert T, Knecht S et al. Phantom-limb pain as a perceptual correlate of cortical reorganization following arm amputation. Nature. 1995; 375: 482-4
89. Stanton AL, Krishnan L, Collins CA. Form or function? Part 1. Subjective cosmetic and functional correlates of quality of life in women treated with breast-conserving surgical procedures and radiotherapy. Cancer. 2001; 91: 2273-81
90. Robb KA, Williams JE, Duvivier V, Newham DJ. A pain management program for chronic cancer-treatmentrelated pain: a preliminary study. Journal of Pain. 2006; 7: 82-90
91. Watson CP, Evans RJ. The postmastectomy pain syndrome and topical capsaicin: a randomized trial. Pain. 1992; 51: 375-9
92. Kalso E, Tasmuth T, Neuvonen PJ. Amitriptyline effectively relieves neuropathic pain following treatment of breast cancer. Pain. 1996; 64: 293-302
93. Tasmuth T, Hartel B, Kalso E. Venlafaxine in neuropathic pain following treatment of breast cancer. European Journal of Pain. 2002; 6: 17-24
94. Reuben SS, Makari-Judson G, Lurie SD. Evaluation of efficacy of the perioperative administration of venlafaxine XR in the prevention of postmastectomy pain syndrome. Journal of Pain and Symptom Management. 2004; 27: 133-9
95. Fassoulaki A, Triga A, Melemeni A, Sarantopoulos C. Multimodal analgesia with gabapentin and local anesthetics prevents acute and chronic pain after breast surgery for cancer. Anesthesia and Analgesia. 2005; 101: 1427-32
96. Fassoulaki A, Sarantopoulos C, Melemeni A, Hogan Q. EMLA reduces acute and chronic pain after breast surgery for cancer. Regional Anesthesia and Pain Medicine. 2000; 25: 350-5
97. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database of Systematic Reviews. 2006; CD006146
98. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. Journal of Clinical Oncology. 2005; 23: 8697-705
99. Bye A, Trope C, Loge JH et al. Health-related quality of life and occurrence of intestinal side effects after pelvic radiotherapy evaluation of long-term effects of diagnosis and treatment. Acta Oncologica. 2000; 39: 173-80
100. Schierle C, Winograd JM. Radiation-induced brachial plexopathy: review. Complication without a cure. Journal of Reconstructive Microsurgery. 2004; 20: 149-52
101. Johansson S, Svensson H, Denekamp J. Timescale of evolution of late radiation injury after postoperative radiotherapy of breast cancer patients. International Journal of Radiation Oncology, Biology, Physics. 2000; 48: 745-50
102. Johansson S. Radiation induced brachial plexopathies. Acta Oncologica. 2006; 45: 253-7
103. Powell S, Cooke J, Parsons C. Radiation-induced brachial plexus injury: follow-up of two different fractionation schedules. Radiotherapy and Oncology. 1990; 18: 213-20
104. Jung BF, Herrmann D, Griggs J et al. Neuropathic pain associated with non-surgical treatment of breast cancer. Pain. 2005; 118: 10-14
105. Johansson S, Svensson H, Denekamp J. Dose response and latency for radiation-induced fibrosis, edema, and neuropathy in breast cancer patients. International Journal of Radiation Oncology, Biology, Physics. 2002; 52: 1207-19
106. Galecki J, Hicer-Grzenkowicz J, Grudzien-Kowalska M et al. Radiation-induced brachial plexopathy and hypofractionated regimens in adjuvant irradiation of patients with breast cancer a review. Acta Oncologica. 2006; 45: 280-4
107. Olsen NK, Pfeiffer P, Johannsen L et al. Radiation-induced brachial plexopathy: neurological follow-up in 161 recurrence-free breast cancer patients. International Journal of Radiation Oncology, Biology, Physics. 1993; 26: 43-9
108. Olsen NK, Pfeiffer P, Mondrup K, Rose C. Radiationinduced brachial plexus neuropathy in breast cancer patients. Acta Oncologica. 1990; 29: 885-90
109. Kori SH, Foley KM, Posner JB. Brachial plexus lesions in patients with cancer: 100 cases. Neurology. 1981; 31: 45-50
110. Cross NE, Glantz MJ. Neurologic complications of radiation therapy. Neurologic Clinics. 2003; 21: 249-77
111. Fathers E, Thrush D, Huson SM, Norman A. Radiationinduced brachial plexopathy in women treated for carcinoma of the breast. Clinical Rehabilitation. 2002; 16: 160-5
112. Qayyum A, MacVicar AD, Padhani AR et al. Symptomatic brachial plexopathy following treatment for breast cancer: utility of MR imaging with surface-coil techniques. Radiology. 2000; 214: 837-42
113. Bajrovic A, Rades D, Fehlauer F et al. Is there a life-long risk of brachial plexopathy after radiotherapy of supraclavicular lymph nodes in breast cancer patients? Radiotherapy and Oncology. 2004; 71: 297-301
114. Pritchard J, Anand P, Broome J et al. Double-blind randomized phase II study of hyperbaric oxygen in patients with radiation-induced brachial plexopathy. Radiotherapy and Oncology. 2001; 58: 279-86
115. Stubblefield MD, Custodio CM. Upper-extremity pain disorders in breast cancer. Archives of Physical Medicine and Rehabilitation. 2006; 87: S96-9
116. Lu L, Gong X, Liu Z et al. Diagnosis and operative treatment of radiation-induced brachial plexopathy. Chinese Journal of Traumatology. 2002; 5: 329-32
117. Kori SH. Diagnosis and management of brachial plexus lesions in cancer patients. Oncology (Williston Park). 1995; 9: 756-60
118. Jackson MB, Pounder D, Price C et al. Percutaneous cervical cordotomy for the control of pain in patients with pleural mesothelioma. Thorax. 1999; 54: 238-41
119. Sanders M, Zuurmond W. Safety of unilateral and bilateral percutaneous cervical cordotomy in 80 terminally ill cancer patients. Journal of Clinical Oncology. 1995; 13: 1509-12
120. Sikora K. Enraged about radiotherapy. British Medical Journal. 1994; 308: 188-9.